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Aim: To determine the patterns of lactoferrin (LF) expression in breast cancer (BC) in relation to biologic properties of the neoplasms 
and clinical features of the disease course. Materials and Methods: Clinical specimens of 266 BC patients (115 patients with 
BC of stages I–II — retrospective study, and 151 BC patients — prospective study) were analyzed. Morphological, immunohisto-
chemical and statistical methods were used. Results: The number of LF-positive tumors in retrospective and prospective groups was 
similar (52.1 and 52.8%, respectively). Among common clinical criteria for prognosis of the disease outcome in BC patients (pa-
tient’s age; stage of the disease; histological type, differentiation grade, receptor status; presence of metastases), a strong correlation 
was found only between expression indexes of LF and estrogen receptors (ER). In ER-positive tumors expression of LF was signifi-
cantly higher than in ER-negative tumors (35 vs 18%). 5-Year survival rate of BC patients was higher in LF-positive group (70 vs 52% 
in LF-negative group). The presence of regional metastasis tended to correlate with an increased number of LF-positive tumors. In the 
patients with invasive ductal carcinoma, expression level of LF moderately correlated with occurrence of luminal A subtype (r = 0.43), 
while in the patients with invasive lobular carcinoma this index strongly correlated with occurrence of luminal B subtype (r = 0.71). 
LF expression correlated positively with low and moderate differentiation grade of luminal B or basal tumors, and negatively with 
luminal B or basal tumors of high differentiation grade (r = −0.57 and −0.63, respectively). Conclusion: It has been shown that 
LF expression in breast tumors correlated with life expectancy of BC patients and important physiologic and clinical features of the 
disease, while the character of such relation strongly depended on molecular phenotype of tumor, i.e. luminal A, luminal B or basal.
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Breast cancer �BC� is the most prevalent oncologic 
pathology in women. It is �elieved that an effectiveness 
of therapy of this disease could �e improved �y the de-
velopment of new means for �iologic correction of iron 
homeostasis as an important factor of sta�le functioning 
of all �ody systems. New knowledge a�out the role of iron 
in the development and progression of tumors has �een 
gained due to the studies of the intracellular content and 
tissue distri�ution of iron-containing proteins and their 
receptors.
It is known that at cellular and molecular levels 
the regulation of iron meta�olism is exerted through the 
�alanced action of iron-containing proteins� including 
transporter proteins. Transport of iron in a protein-�ound 
form minimi�es its capa�ility for participation in the reac-
tions of free-radical oxidation� and therefore decreases 
possi�le oxidative damage of cells and tissues of an or-
ganism [�].
While the meta�olic patterns of such iron-containing 
proteins as ferritin� transferrin� ferroportin in BC patients 
are studied in detail [�]� the role of lactoferrin ���� in patho-
genesis� clinical course and prognosis of BC is still poorly 
understood. �� is an iron-�inding glycoprotein of trans-
ferrin family of iron transporter proteins� with a molecular 
weight of 7�.� kD composed of a single polypeptide 
chain. �� contains 7�� aminoacids and forms two ho-
mological domains� N- and C-parts of which contain 
an iron-�inding center and have a special function [�].
Different �� isoforms have �een identified. ��-� is ca-
pa�le to �ind iron ions �ut has no ri�onuclease activity 
while isoforms ��-β and -γ exert ri�onuclease activity �ut 
are incapa�le to �ind metal ions [4]. Apart from this� the 
protein could exist in iron-saturated form �hololactoferrin� 
or iron-unsaturated form �apolactoferrin�. One molecule 
of the protein could �e �ound with two ions of iron� cop-
per� �inc or other metals.
Also it has �een shown that some functional features 
of �� depend on its oligomeric state. As a monomer� 
�� is capa�le to �ind with DNA and regulate granulo-
poiesis� while tetrameric form of �� lacks such fea-
tures [5]. It has �een esta�lished that the process 
of conformational rearrangement of �� with formation 
of mono-� di-� tri-� or tetrameric forms requires adenosine 
triphosphate [�].
In adult human �ody� �� is stored in neutrophils� 
specific �secondary� granules of which contain large 
amounts of ��. �� content may vary depending on gen-
der and age� however� the results of different studies 
are contradictory. After degranulation of neutrophils� 
�� is released into the �lood and is quickly �ound to and 
a�sor�ed �y parenchymatous cells of liver and spleen. 
Under normal conditions� �lood plasma �� concentra-
tion is �.4��.� mg/l. There are some data on significant 
elevation of �� content in �iological fluids �up to ��� mg/l� 
upon some pathologies� including cancer� and especially 
upon inflammatory states� therefore �� content could 
�e used as a �iochemical marker of inflammation [7].
An important feature of �� is its capa�ility to �ind 
with nucleic acids� especially with dou�le-stranded 
DNA. �� is internali�ed with participation of �� recep-
tor along with iron ions �ound with its molecule. Also� 
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�� regulates the concentration of iron ions in �lood and 
secretory fluids� exerts antimicro�ial and antiviral action 
and is considered as an important immune factor of milk. 
It directly participates in defense reactions of a �ody 
and mediates the development of cellular immunity. 
�� interacts with polyamines and heparin. Apart from this� 
�� exerts antioxidant� immunomodulating and anticancer 
activities [�]. �� is capa�le to enter cell nuclei and activate 
transcription of specific genes� �ut such target genes 
have not �een yet identified.
Therefore� �� is a protein with a wide spectrum of �io-
logic functions. The role of �� in the clinical course of BC re-
mains unclear. There are a few stu dies of �� in BC cells 
in vitro� in particular� �� increases migration and invasion 
of triple receptor-positive and receptor-negative BC cells 
[9]. Also it has �een shown that �� isolated from cow 
milk is capa�le to decrease the via�ility of human �reast 
carcinosarcoma H�57�T cells and human ductal �reast 
epithelial tumor T47D cells �y 47 and 54%� respectively� 
and to induce �-fold increased apoptosis in these cells 
[��]. The results of our studies have shown that exogenous 
�� can modify the molecular profile and invasive properties 
of cultured BC cells with different potential of malignancy� 
including drug-resistant MC�-7/Cp and MC�-7/Dox cell 
lines [��]. Other researchers have demonstrated that 
recom�inant human �� variants affect the properties 
of tumor cells in vitro in a way that could �e considered 
antitumorigenic [��� ��].
Presently there are scarce or no data on the role 
of �� in the pathogenesis of BC� relation �etween 
�� content and clinical� morphological and molecular-
�iologic characteristics of BC at different stages of the 
disease� as well as �� validity as prognostic criterion for 
clinical course of BC. Therefore� the aim of the study 
was to analy�e the patterns of �� expression in tumor 
cells of BC patients taking into account their �iological 
properties and clinical features of the disease.
MATERIALS AND METHODS
The clinical specimens of ��� BC patients was ana-
ly�ed [�4]. The assessment of prognostic value of �� for 
the disease outcome was �ased on a retrospective 
analysis of the data of ��5 BC patients stages I�II treated 
in Kyiv Municipal Clinical Oncologic Center in ���5����7. 
A prospective study of �5� BC patients treated in the 
same clinics in ��������4 was aimed at an assessment 
of the relation �etween �� expression in tumors of dif-
ferent molecular phenotype and clinical characteristics 
of BC affecting the course of the disease. All patients 
provide an informed written consent on the use of indi-
vidual clinical data for scientific purposes.
All patients received surgical treatment �quadrant- 
or lumpectomy with regional lymph node dissection� 
radical mastectomy �y Madden�. The patients with 
BC of stages І�ІІ were not treated with neoadjuvant 
therapy. Adjuvant polychemotherapy was performed: 
CM� �cyclophosphamide� methotrexate� fluorouracyl�� 
CA� �cyclophosphamide� doxoru�icine� fluorouracyl�� 
4�� courses; radiotherapy on postoperative cicatrix 
and the �one of regional metastases at a total dose 
of 4��44 �y. The patients with positive expression of hor-
mone receptors in removed tumor tissue were treated 
with prolonged hormonal therapy �y standard scheme 
�tamoxiphene� aromatase inhi�itors� depending on the 
individual clinical data.
�eneral clinico-pathological characteristics of BC pa-
tients are presented in Ta�le �. As one may see� the pa-
tients from �oth groups were of similar age� the majority 
of them �eing at menopause. By histological structure� 
the most common BC type was invasive ductal cancer 
of moderate differentiation grade. By the data of molecu-
lar-�iologic study� luminal А su�type was diagnosed 
in the majority of BC patients from �oth groups.
Table 1. Clinico-pathologic characteristics of BC patients
Indexes
Retrospective 
group
Prospective  
group
Number of patients
n % n %
Total number of patients 115 100 151 100
Average age, years 54.2 ± 3.1 56.5 ± 9.6
Age range, years 23–75 28–89
Active menstrual cycle 39 33.9 29 19.2
Menopause 76 66.1 122 80.8
Stage І (T1N0M0) 27 23.5 47 31.1
Stage ІІ (T2N1–2M0)
Т2а (T1N0M0)
Т2b (T2N1–2M0)
88
53
35
76.5
46.0
30.5
104
81
23
68.9
53.6
15.3
Invasive ductal carcinoma 86 74.8 101 66.9
Invasive lobular carcinoma 29 25.2 50 33.1
Differentiation grade G1 (high) 32 27.8 42 27.8
Differentiation grade G2 (moderate) 59 51.3 78 51.7
Differentiation grade G3 (low) 24 20.9 31 20.5
Molecular subtype
Luminal A 53 46.0 81 53.6
Luminal B 31 27.0 35 23.2
Basal 31 27.0 35 23.2
All patients were examined with the use of common 
clinical and la�oratory methods in accordance with 
the standards for diagnostics and therapy of cancer 
patients approved �y the orders of Ministry of Health 
No.�4� of �7.�7.�99� and No.554 of �7.�9.���7. 
The stage of cancer was estimated according to Inter-
national TNM classification ������.
�or morphologic research� surgically removed tumor 
specimens was fixed in ��% neutral formaline solution 
and further treated �y standard histological method. 
The preparations were prepared from paraffine �locks� 
stained with hematoxylin and eosin� and examined using 
light microscopy.
Immunohistochemical determination of �� expres-
sion in the tumors was performed with the use of standard 
streptavidine-�iotine-peroxydase method on histological 
slides prepared from paraffine �locks after their fixation 
in ��% solution of neutral formaline. The 4�5 mm histo-
logic sections were placed on �uper �rost Plus slides 
��ermany�. �urther procedures were performed �y rou-
tine technique. Anti-�� MoA�s �A�cam� U�A� were used 
as primary anti�odies. Visuali�ation was done using 
EnVision system �Dako��AB� system� Denmark�. After 
detection of peroxydase activity� the slides were stained 
with Mayer’s hematoxylin. Assessment of �� expression 
was performed �y semiquantitative method. In each 
histological preparation� �� expression was analy�ed 
per ���� tumor cells� the num�er of immunopositive and 
immunonegative cells was expressed in percents ac-
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counting for the degree of the marker expression �high� 
moderate� strong�. If the num�er of immunopositive cells 
was higher than ��%� �� expression was considered 
as a strong positive one.
�or immunohistochemical study of other markers 
we have used anti�odies against estrogen receptors 
�ER� �clone �D5�� progesterone receptors �PR� �clone 
PgR����� epidermal growth factor receptor HER�/neu 
�clone c-er�B-��� proliferation marker Кі-�7 �clone 
MIB-�� from DakoСytomation� Denmark. Assessment 
of expression of mentioned proteins in �reast tumors 
was performed �y counting immunopositive cells using 
H-�core method [�5]. Expression from � to ��� scores 
was considered low� ������� — moderate� and > ��� — 
high. In the study light microscope Primo �tar �Zeiss� 
�ermany�� magnification ×����4��� was used.
�tatistical analysis of the data was done with the use 
of �TATI�TICA �.� program. The relation �etween the 
indexes was assessed using Pearson’s coefficient� its 
significance analy�ed with the use of χ² test.
RESULTS AND DISCUSSION
Immunohistochemical detection of �� in BC samples 
revealed a positive ��-specific reaction in cytoplasm 
of tumor cell in �oth groups of the patients. The num�er 
of ��-positive ����� tumors in retrospective and pro-
spective groups did not differ and at average was equal 
to 5�.� and 5�.�%� respectively.
In BC patients from group �� �� expression indexes 
were analy�ed in relation to a num�er of clinical charac-
teristics each of which affecting the clinical course of the 
disease� in particular� age and menstrual function of the 
patients� the stage of the disease� histological type of the 
tumor� its differentiation grade and degree of malignancy� 
metastasis in regional lymph nodes� receptor status 
of tumor cells.
The results of correlation analysis evidenced 
on an a�sence of the difference in the num�ers of ��� 
tumors dependent on the age of patients with preserved 
reproductive function ��4 �4�.�%�� and patients at meno-
pause �4� �45.4%��. No correlation was found �etween 
�� expression in tumor� BC stage and histological type 
of BC. There was o�served a tendency �etween an in-
creased num�er of ��� tumors in the patients with high 
differentiated BC ��9 �47.5%�� compared to these with 
moderately differentiated tumors ��7 �4�.5%�� and low 
differentiated BC ��7 �4�.4%��.
The num�er of ��� tumors ���%� tended to increase 
if regional lymph node metastasis N� was present.
As far as receptor status of BC is considered as the 
most important prognostic marker and an o�jective 
criterion for hormonal therapy [��]� we have studied 
a relation �etween an expression of ER in BC cells and 
�� expression in tumor cells of these patients. Interes-
tingly� in ER-positive �ER�� tumors an expression level 
of �� was found to �e significantly� nearly twice higher 
��5%� than in ER-negative �ER−� tumors ���%� ��ig. ��.
According to the data of literature� regulation 
of �� synthesis depends on histological type of the cells 
producing this protein� while amount of �� synthesi�ed 
in mammary gland is controlled �y prolactin� and its 
synthesis in reproductive tissue is regulated �y estro-
gens [�7]. Also� it has �een reported that �� is a ligand 
for specific receptors on cell surface� which are selective 
for each histological type [��]. This o�servation could 
possi�ly explain a high expression level of �� in RE� BC.
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Fig. 1. �� expression in ER� and ER� �reast tumors
Also� we have studied whether �� expression 
in BC tissue could �e related to survival time of BC pa-
tients� the most valid clinical criterion [�9]. An analysis 
of Kaplan — Meyer’s curves for the groups of BC patients 
with ��� or ��-negative ���−� tumors ��ig. �� has shown 
that 5-year survival was higher in ��� group. We suppose 
that higher �� levels could increase functional activity 
of immune system� as it has �een detected in the case 
of inflammation when increased �� levels are related 
to antiinflammatory cytokines [��]. It could �e con-
sidered reasona�le as far as some researchers claim 
common features of inflammation and cancer [��]. 
A relation �etween �� and antiinflammatory cytokines 
has �een found in the studies of lymphoproliferative 
diseases [��] and malignant melanoma [��]. �urther 
studies of �� expression in BC tissue and its relation 
to survival of BC patients are required.
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Fig. 2. Overall survival of BC patients depending on �� and ER ex-
pression in tumor cells
Presently BC is considered as a complex pathology 
with various �iologic su�types which differ in the causes 
of development� clinical and molecular features� have dif-
ferent prognosis and require special therapeutic strate-
gies [�4� �5]. In recent years a classification of molecular 
portraits of BC proposed �y Perou et al. [��] �ecame 
popular� �ecause different molecular BC su�types 
�luminal А and В� �asal� Her�� differ not only �y molecular 
markers �ut also �y specific �iology� which is supported 
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�y clinical o�servations [�7]. In particular� it has �een 
shown that molecular su�type may serve as an inde-
pendent prognostic criterion and a prediction factor 
of an effectiveness of the therapy [��].
In view of the foregoing� we attempted the pro-
spective study of the relation �etween �� expression 
in tumors and clinical features of BC including molecular 
phenotype of the tumors. �� expression was a�out the 
same in the tumors of patients aged 4��5� and ����9� 
i.e.� at premenopausal and postmenopausal periods 
��ig. ��. Nevertheless� the percentage of ��� tumors 
decreased in the group of BC patients aged 5����� i.e. 
at menopause. The stage І and ІІ groups differed neither 
�y H-score of �� positivity� nor �y the percentage of ��� 
tumors �Ta�le ��. In �oth groups �stage I and II� the tu-
mors with low �� expression were prevalent ��5.� and 
5�.7%� respectively� �see Ta�le ��.
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Fig. 3. Expression of �� depending on the age of BC patients and 
menstrual function. *The difference is significant compared to other 
groups �p < �.�5�
Table 2. Expression of LF in breast tumors of different histological type 
and at different stage of the disease
Clinical indexes
Number  
of patients
Expression patterns of LF  
in breast tumors
n %
Total number 
of LF+ cells 
(by H-Score)
Number 
of tumors 
with low 
LF ex-
pression, 
%
Number 
of tumors with 
moderate and 
high LF ex-
pression, %
Stage of the disease
І
ІІ
35
75
31.8
68.2
172.3 ± 16.7
174.5 ± 14.4
65.8
58.7
34.2
41.3
Histological type of the tumor
Invasive ductal  
carcinoma
Invasive lobular 
carcinoma
75
25
70.9
22.7
187.2 ± 16.5*
143.2 ± 18.3
55.12*
76.92*
44.87*
23.07
Note: *the difference is significant compared to invasive lobular carcinoma 
(р < 0.05)
Comparison of �� expression in the tumors of dif-
ferent histological type revealed significantly higher 
num�er of ��� cells in invasive ductal carcinoma 
vs invasive lo�ular carcinoma �see Ta�le ��. In inva-
sive ductal carcinoma� the percent of the tumors with 
moderate and high �� expression was significantly 
higher than the percent of tumors with low �� expres-
sion �55.�� vs 44.�7%�. In invasive lo�ular carcinoma� 
the tumors with low �� expression were prevalent 
�7�.9� vs ��.�7%�. Also� it was shown that in the tu-
mors of low differentiation grade� �� expression was 
significantly higher than in the tumors of high or mo-
derate differentiation grade �Ta�le ��.
Table 3. Expression patterns of LF in breast tumors of different differentiation 
grade
Differen-
tiation 
grade 
of the tu-
mor
Number of patients Expression patterns of LF in breast tumors
n %
Total number 
of LF+ cells 
(by H-Score)
Number 
of tumors 
with low 
LF expres-
sion, %
Number 
of tumors 
with high 
LF expres-
sion, %
High
Moderate
Low
22
57
32
20.00
51.81
29.09
146 ± 21.5
150 ± 16.2
162 ± 15.1*,**
63.4
62.0
44.5
36.6
38.0
55.5
Note: *the difference is significant compared to the highly differentiated tu-
mors (p < 0.05).
**The difference is significant compared to moderately differentiated tumors 
(p < 0.05)
An analysis of clinical data of BC patients in an as-
pect of molecular phenotype of the tumor has shown 
that median age of the patients with luminal А and 
В BC su�types was somewhat higher than 55 years� 
while the patients with �asal phenotype were signifi-
cantly older �Ta�le 4�.
Table 4. Clinical characteristics of the BC patients with different molecular tu-
mor subtypes
Clinical indexes
Molecular subtype of the tumor
Luminal А Luminal В Basal
n % n % n %
Average age, years 59.57 ± 8.7 56.55 ± 5.4 67.16 ± 13.5
Menstrual function:
premenopause
menopause
postmenopause
21
23
36
26.25
28.75
45.00
6
5
7
33.33
27.75
40.92
3
3
29
8.3
8.3
83.3
Stage:
І
ІІ
27
53
33.75
66.25
3
15
16.65
83.25
15
20
42.85
57.41
Histological type:
invasive lobular carcinoma
invasive ductal carcinoma
22
52
27.5
65
4
14
22.2
77.7
15
20
42.85
57.41
Differentiation grade
high
moderate
low
17
43
20
21.25
53
25
3
14
1
16.65
77.7
5.55
13
10
12
37.14
28.57
34.28
The majority of the patients grouped �y receptor 
status of the tumor were at postmenopausal period and 
with prevalently �asal BC phenotype. A large majority 
of the patients with luminal or �asal tumor su�type were 
at stage ІІ� luminal B su�type �eing much more frequent. 
The percentage of luminal А and luminal В molecular 
su�types in invasive ductal carcinoma was respectively 
�.� and �.4 times higher than in invasive lo�ular carci-
noma. Also� luminal А and luminal В su�types occurred 
more frequently in moderately differentiated tumors 
compared to those with high or low differentiation grade� 
while the percentage of �asal su�type did not differ sig-
nificantly �etween the tumors of different differentiation 
grade �see Ta�le 4�.
An analysis of �� expression did not reveal significant 
differences in num�er of ��� cells measured �y H-�core 
�etween BC of different molecular phenotypes �Ta�le 5�.
We also analy�ed expression of �� in BC with different 
molecular phenotype taking into acount the most im-
portant prognostic clinical indexes �menstrual function� 
disease stage� histological type and differentiation grade 
of a tumor�. It has �een shown that expression of �� in the 
luminal А tumors was equally frequent in the patients 
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at premenopausal and postmenopausal periods� and 
was at average higher than in the patients at menopause. 
Expression of �� in the luminal В tumors did not depend 
on menstrual function and was significantly higher than 
in the luminal А tumors. In the tumors with �asal pheno-
type� no expression of �� was registered in the patients 
at premenopausal period while in the patients at meno-
pause or postmenopausal period high expression levels 
of �� were o�served which were somewhat lower than 
that in luminal В tumors �Ta�le ��.
Table 5. Expression of LF in breast tumors of different molecular subtypes
Molecular 
subtype 
of the tu-
mor
Number  
of tumors Indexes of LF expression in the tumors
n % Number of LF+ cells (by H-Score)
Number of tumors with 
moderate and high 
LF expression, %
Luminal А 81 53.0 174.5 ± 18.2 35.7
Luminal В 35 23.5 168.0 ± 13.2 46.4
Basal 35 23.5 175.2 ± 16.7 41.6
Comparison of �� expression in the tumors of different 
molecular phenotype �etween the groups with different 
disease stage did not reveal the differences �etween the 
stages I and II� �ut it has �een noted that at �oth stages 
expression of �� in tumors with luminal В and �asal su�-
types was higher compared to su�type A tumors.
In cases of invasive ductal BC� expression of �� was 
significantly higher in luminal В tumors than luminal А� 
and this index was equal in �asal and luminal A su�types. 
In the case of invasive lo�ular carcinoma� expression 
of �� was significantly lower in �asal su�type compared 
to luminal В su�type� �ut was significantly higher than 
in luminal А su�type �see Ta�le ��.
An analysis of �� expression in tumors of different 
differentiation grade has shown that in the groups with 
moderate and low differentiation grades the highest 
expression of �� was present in luminal В su�type com-
pared to su�type А. In luminal su�type А tumors of high 
differentiation grade the indexes of �� expression were 
slightly lower than these in tumors of low and moderated 
differentiation grades and equal to these in �asal tumors 
�see Ta�le ��.
The correlation analysis did not demonstrate cor-
relation of �� expression with the stage of the disease 
�I or II� in all molecular su�types. In invasive ductal carci-
noma �� expression correlated with occurrence of lumi-
nal A su�type while in invasive lo�ular carcinoma expres-
sion of �� showed a positive correlation with occurrence 
of luminal В su�type. In the tumors of �oth histological 
types with �asal molecular phenotype no correlation was 
found �Ta�le 7�. �� expression was in a strong positive 
correlation with occurrence of low and moderate dif-
ferentiation grade of luminal B or �asal tumors.
Therefore� the present research has shown that 
expression of �� in BC correlated with some important 
physiologic and clinical indexes of the disease. The pat-
terns of correlation strongly depended on molecular phe-
notype of this pathology� i.e. luminal A� luminal B or �asal.
Table 7. Correlation between expression of LF in breast tumors of different 
molecular subtype and clinical and morphological characteristics 
of BC patients
Molecu-
lar subtype 
of the tu-
mor
Stage  
of the disease
Histological type 
of carcinoma Differentiation grade
І ІІ Invasive ductal
Invasive 
lobular High
Mode-
rate Low
Luminal А 0.11 0.2 0.43 0.22 0.27 0.18 0.16
Luminal В 0.17 0.23 0.14 0.71 –0.57 0.68 0.23
Basal 0.026 0.14 0.24 0.21 –0.63 0.73 0.06
According to the data of epidemiologic studies� the 
development of each particular molecular BC phenotype 
could �e affected �y many factors including physiologic� 
constitutive and genetic ones [�9]. �or example� high 
waist-to-hip ratio is a risk factor for postmenopausal lu-
minal and �asal carcinoma. It is known that �asal BC su�-
type develops more frequently in young Afro-American 
women compared to white women. There are some 
studies repor ting that �asal carcinoma development could 
�e prevented �y weight control and prolonged �reast 
feeding [��]. By the data of genetic studies� the majo -
rity of BRCA1-associated tumors are of �asal su�type� 
while in the cases with mutated BRCA2 the tumors are 
mostly of luminal А and В su�types [��]. In general� the 
data of literature evidence that molecular pathogenesis 
of BC strongly depends on physiologic and genetic factors 
[�4]� and molecular BC su�types represent different forms 
of the disease with different etiology and pathogenesis.
Along with this� some recent pu�lications demon-
strate that �iologic heterogeneity of BC could as well 
�e affected �y the heterogeneity of expression of mo-
lecular markers that determine BC phenotype� and im-
portant signal pathways involved in the development and 
progression of the tumors [��� ��]. In particular� �y the 
data of cluster microanalysis� it has �een considered 
reasona�le to classify Her�-positive su�type into three 
separate su�types �ecause one of them is characteri�ed 
�y more unfavora�le prognosis than two others [�4]. 
Also� one should take into account the existence of two 
forms of ER — ER� and ERβ� as far as the latter is dif-
ferently expressed in molecular su�types of BC [�5]. 
Hyper expression of ERβ is the highest in �asal BC su�-
type and serves as a negative prognostic factor; �y multi-
factor analysis� it is considered to �e an independent risk 
factor of BC. It is supposed that screening of BC patients 
�y expression of ERβ and ER� may help to assess pro-
liferative activity of the tumors and to make prognostic 
indexes more accurate.
Table 6. Expression of LF in breast tumors of different molecular subtypes and clinical and morphological characteristics of BC patients
Molecu-
lar subtype 
of the tumor
Menstrual function Stage of the disease
Tumor morphology
Histological type  
of carcinoma Differntiation grade
Premeno-
pause Menopause
Postmeno-
pause І ІІ
Invasive  
ductal
Invasive  
lobular High Moderate Low
Luminal А 181.3 ± 15.2 160.1 ± 8.0 184.2 ± 17.2 186.3 ± 14.8 180.3 ± 14.4 172.3 ± 21.8 152.4 ± 10.8 183.2 ± 15.3 176.2 ± 17.6 172.4 ± 16.1
Luminal В 235.4 ± 10.2 241.3 ± 16.5 221.5 ± 14.2 216.4 ± 14.0 221.3 ± 12.1 206.1 ± 17.4* 231.2 ± 13.3* 198.2 ± 18.2 223.4 ± 14.2* 229.1 ± 11.7*
Basal − 215.2 ± 18.3 210.7 ± 15.7 198.5 ± 13.7 203.9 ± 18.1 175.1 ± 12.1 182.1 ± 19.6 180.0 ± 15.6 210.0 ± 12.6* 215.6 ± 14.2*
Note:*the difference is significant compared to other molecular subtypes (p < 0.05).
��� Experimental Oncology ��� �������� ���� ��eptem�er�
Taking into account �iological properties of �� and 
wide range of its functional activities� we propose to con-
sider �� as an integral �iological index reflecting dif-
ferent changes associated with tumor cell heterogeneity 
in a neoplasm� and with individual response of an orga-
nism on particular tumor phenotype. �uch idea is sup-
ported �y the recent data on capa�ility of DNA� different 
nucleotides and oligosaccharides to affect the formation 
of �� oligomers that differ �y antioxidant and antitumor 
activities and �y their interaction with the components 
of immune system [��].
The results of the present study on the correlation 
�etween the expression of �� in �reast tumors with life 
expectancy of BC patients are of special importance. 
It seems reasona�le to find the ways of �� correction 
in BC patients taking into account the individual patterns 
of clinical course of the disease and tumor heterogeneity.
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